Chocolate Cravings Rise Among GLP-1 Drug Users: A Sweet Surprise for Lindt

Chocolate sales are increasing more rapidly among U.S. users of GLP-1 weight-loss drugs compared to the general population, according to Swiss chocolatier Lindt & Spruengli. The rise contradicts expectations that these drugs would curb confectionery demand. Premium chocolate sales among GLP-1 users jumped nearly 17% in 2025.

There's a new sweet trend in the U.S., as chocolate sales surge among users of GLP-1 weight-loss drugs, a development noted by Swiss chocolatier Lindt & Spruengli. This trend defies predictions that such drugs would decrease chocolate demand.

An internal Lindt study revealed that 15% of U.S. households using GLP-1s account for 17.5% of chocolate sales. The company's data showed a nearly 17% increase in premium chocolate purchases among GLP-1 users in 2025, a significant jump compared to a 6.5% rise among non-users.

Market expectations, like those from Berenberg analysts, foresaw a negative impact on the food industry with the advent of oral GLP-1 weight-loss drugs. They projected a drag on Lindt's sales volumes by 0.9 percentage points in 2027. However, these new findings suggest broader adoption of GLP-1 pills, which may affect these forecasts.

(With inputs from agencies.)